Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds

Amino Acids

Volumn 41, Issue 1, 2011, Pages 29-41

  Pinto, John T ^a   Lee, Jeong In ^a   Sinha, Raghu ^b   MacEwan, Melanie E ^a   Cooper, Arthur J L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Keto methylselenobutyrate; Glutamine transaminase K; Glutamine transaminase L; Histone deacetylase; L Amino acid oxidase; L Selenomethionine; Methylselenopyruvate; Prostate cancer; Se Methyl L selenocysteine

Indexed keywords

2 OXOACID; ALCOHOL DERIVATIVE; ALPHA KETO GAMMMA METHYLSELENOBUTYRATE; ALPHA TOCOPHEROL; AMINO ACID OXIDASE; AMMONIA; BUTYRIC ACID; CYSTATHIONINE GAMMA LYASE; CYSTEINE CONJUGATE BETA LYASE; CYSTEINE DERIVATIVE; GLUTAMINE PHENYLPYRUVATE AMINOTRANSFERASE; GLUTATHIONE PEROXIDASE; HISTONE DEACETYLASE; HISTONE H3; METHIONINE GAMMA LYASE; METHYLSELENOCYSTEINE; METHYLSELENOL; METHYLSELENOPYRUVATE; ORGANOSELENIUM DERIVATIVE; PYRIDOXAL 5 PHOSPHATE; PYRUVIC ACID; SELENIUM DERIVATIVE; SELENOCYSTEINE; SELENOMETHIONINE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ALCOHOL PRODUCTION; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER PREVENTION; CANCER RISK; CATALYSIS; CELL PROLIFERATION; COLON CANCER; DIABETES MELLITUS; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME SPECIFICITY; HISTONE ACETYLATION; HUMAN; HYDROPHOBICITY; METABOLITE; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TARGET CELL; TRANSAMINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; KETO ACIDS; ORGANOSELENIUM COMPOUNDS;

EID: 79960402611     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-010-0578-3     Document Type: Review

References (95)

1. Blarzino C, Coccia R, Pensa B, Cini C, De Marco C (1994) Selenomethionine as substrate for glutamine transaminase. Biochem Mol Biol Int 32:79-86 (Pubitemid 24077245)
2. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784 (Pubitemid 44348499)
3. Boulland ML, Marquet J, Molinier-Frenkel V, Möller P, Guiter C, Lasoudris F, Copie-Bergman C, Baia M, Gaulard P, Leroy K, Castellano F (2007) Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. Blood 110:220-227 (Pubitemid 47026838)
4. Buggy JJ, Sideris ML, Mak P, Lorimer DD, McIntosh B, Clark JM (2000) Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J 350:199-205
5. Carbonnelle-Puscian A, Copie-Bergman C, Baia M, Martin-Garcia N, Allory Y, Haioun C, Crémades A, Abd-Alsamad I, Farcet JP, Gaulard P, Castellano F, Molinier-Frenkel V (2009) The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia 23:952-960
6. Cavallini D, De Marco C, Moldovi B, Mori BG (1960) The cleavage of cystine by cystathionase and the transsulfuration of hypotau-rine. Enzymologia 22:161-173
7. Chen Y, Maret W (2001) Catalytic selenols couple the redox cycles of metallothionein and glutathione. Eur J Biochem 268:3346-3353 (Pubitemid 32823010)
8. Chen YC, Sosnoski DM, Gandhi UH, Novinger LJ, Prabhu KS, Mastro AM (2009) Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer. Carcino-genesis 30:1941-1948
9. Clark JP, Cooper CS (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6:429-439
10. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957-1963 (Pubitemid 26427723)
11. Combs GF Jr (2004) Status of selenium in prostate cancer prevention. Br J Cancer 91:195-199 (Pubitemid 39037057)
12. Commandeur JNM, Andreadou I, Rooseboom M, Out M, de Leur LJ, Groot E, Vermeulen NPE (2000) Bioactivation of selenocysteine Se-conjugates by a highly purified rat renal cysteine conjugate b-lyase/glutamine transaminase K. J Pharmacol Exp Ther 294:753-761 (Pubitemid 30490854)
13. Cooper AJL (1988) Glutamine aminotransferases and x-amidases. In: Kvamme E (ed) Glutamine and glutamate in mammals. CRC Press, Boca Raton, pp 33-52
14. Cooper AJL (1998) Mechanisms of cysteine S-conjugate b-lyases. Adv Enzymol Relat Areas Mol Biol 72:199-238
15. Cooper AJL (2004) The role of glutamine transaminase K (GTK) in sulfur and a-keto acid metabolism in the brain, and in the possible bioactivation of neurotoxicants. Neurochem Int 44:557-577
16. Cooper AJL, Anders MW (1990) Glutamine transaminase K and cysteine conjugate b-lyase. Ann N Y Acad Sci 585:118-127 (Pubitemid 20175892)
17. Cooper AJL, Meister A (1981) Comparative studies of glutamine transaminases from rat tissues. Comp Biochem Physiol 69B:137-145
18. Cooper AJL, Pinto JT (2005) Aminotransferase, L-amino acid oxidase and b-lyase reactions involving L-cysteine S-conjugates found in allium extracts. Relevance to biological activity? Biochem Pharmacol 69:209-220 (Pubitemid 41556567)
19. Cooper AJL, Pinto JT, Krasnikov BF, Niatsetskaya ZV, Han Q, Li J, Vauzour D, Spencer JPE (2008) Substrate specificity of human glutamine transaminase K as an aminotransferase and as a cysteine S-conjugate b-lyase. Arch Biochem Biophys 474:72-81
20. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981-989 (Pubitemid 350080267)
21. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC; Nutritional Prevention of Cancer Study Group (2003) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91:608-612 (Pubitemid 36583728)
22. Duley JA, Holmes RS (1976) L-a-Hydroxyacid oxidase isozymes. Purification and molecular properties. Eur J Biochem 63:163-173
23. El-Bayoumy K (2009) The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer 61:285-286
24. Frew AJ, Johnstone RW, Bolden JE (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280:125-133
25. Ganther HE (1999) Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 20:1657-1666 (Pubitemid 29410542)
26. Gasparian AV, Yao YJ, Lü J, Yemelyanov AY, Lyakh LA, Slaga TJ, Budunova IV (2002) Selenium compounds inhibit IjB kinase (IKK) and nuclear factor-jB (NF-jB) in prostate cancer cells. Mol Cancer Ther 1:1079-1087
27. Giacinti L, Vici P, Lopez M (2008) Epigenome: a new target in cancer therapy. Clin Ter 159:347-360
28. Hatfield DL, Gladyshev VN (2009) The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv 9:18-21
29. Huang W, Waknitz M (2009) ETS gene fusions and prostate cancer. Am J Transl Res 1:341-351
30. Huber RE, Criddle RS (1967) Comparison of the chemical properties of selenocysteine and selenocystine with their sulfur analogs. Arch Biochem Biophys 122:164-173
31. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76 (Pubitemid 40215840)
32. Ip C (1998) Lessons from basic research in selenium and cancer prevention. J Nutr 128:1845-1854 (Pubitemid 28509845)
33. Ip C, Thompson HJ, Shu Z, Ganther HE (2000) In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60:2882-2886 (Pubitemid 30395810)
34. Jiang C, Wang Z, Ganther H, Lü J (2002) Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 1:1059-1066
35. Keppler BR, Archer TK (2008) Chromatin-modifying enzymes as therapeutic targets-Part 2. Expert Opin Ther Targets 12:1457-1467
36. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C (2001) SELECT: the next prostate cancer prevention trial Selenum and Vitamin E Cancer Prevention Trial. J Urol 166:1311-1315 (Pubitemid 32862164)
37. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C (2003) SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 21:59-65 (Pubitemid 41121900)
38. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E (2009) Serum selenium concentrations, diabetes in U.S. adults: National Health, Nutrition Examination Survey (NHANES) 2003-2004. Environ Health Perspect 117:1409-1413
39. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468
40. Lee JI, Nian H, Cooper AJL, Sinha R, Dai J, Bisson WH, Dashwood RH, Pinto JT (2009) a-Keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res 2:683-693
41. Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, Combs GF Jr, Lü J (2008) Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 29:1005-1012 (Pubitemid 351982246)
42. Lichtenberg LA, Wellner D (1968) A sensitive fluorometric assay for amino acid oxidase. Anal Biochem 26:313-319
43. Lillig CH, Holmgren A (2007) Thioredoxin and related molecules- from biology to health and disease. Antioxid Redox Signal 9:25-47 (Pubitemid 44901873)
44. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA Jr (2005) Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97:94-102 (Pubitemid 40277089)
45. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39-51
46. Liu P, Li S, Gan L, Kao TP, Huang H (2008) A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res 68:10290-10299
47. Lu J, Jiang C (2001) Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects. Nutr Cancer 40:64-73 (Pubitemid 34037516)
48. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107:600-608
49. Mason JM, Naidu MD, Barcia M, Porti D, Chavan SS, Chu CC (2004) IL-4-induced gene-1 is a leukocyte L-amino acid oxidase with an unusual acidic pH preference and lysosomal localization. J Immunol 173:4561-4567 (Pubitemid 39280688)
50. Meister A, Sober HA, Tice SV, Fraser PE (1952) Transamination and associated deamidation of asparagine and glutamine. J Biol Chem 197:319-330
51. Moeller T (1963) Inorganic chemistry: an advanced textbook. Wiley, New York, p 135
52. Myzak MC, Karplus PA, Chung FL, Dashwood RH (2004) A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64:5767-5774 (Pubitemid 39095576)
53. Nagaoka K, Aoki F, Hayashi M, Muroi Y, Sakurai T, Itoh K, Ikawa M, Okabe M, Imakawa K, Sakai S (2009) L-Amino acid oxidase plays a crucial role in host defense in the mammary glands. FASEB J 23:2514-2520
54. Nian H, Delage B, Pinto JT, Dashwood RH (2008) Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deace-tylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 29:1816-1824
55. Nian H, Delage B, Ho E, Dashwood RH (2009a) Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 50:213-221
56. Nian H, Bisson WH, Dashwood W-M, Pinto JT, Dashwood RH (2009b) a-Keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis 30:1416-1423
57. Ohta Y, Kobayashi Y, Konishi S, Hirano S (2009) Speciation analysis of selenium metabolites in urine and breath by HPLC- and GC-inductively coupled plasma-MS after administration of seleno-methionine and methylselenocysteine to rats. Chem Res Toxicol 22:1795-1801
58. Okuno T, Motobayashi S, Ueno H, Nakamuro K (2005) Identification of mouse selenomethionine a, c-elimination enzyme: cystathio-nine c-lyase catalyzes its reaction to generate methylselenol. Biol Trace Elem Res 108:245-257 (Pubitemid 41752516)
59. Papp LV, Lu J, Holmgren A, Khanna KK (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9:775-806 (Pubitemid 46919583)
60. Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K (2007) Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Int J Cancer 120:1410-1417 (Pubitemid 46355374)
61. 3 receptor. Cancer Res 62:7050-7058 (Pubitemid 35424100)
62. Ravn-Haren G, Krath BN, Overvad K, Cold S, Moesgaard S, Larsen EH, Dragsted LO (2007) Effect of long-term selenium yeast intervention on activity and gene expression of antioxidant and xenobiotic metabolizing enzymes in healthy elderly volunteers from the Danish Prevention of Cancer by Intervention by Selenium (PRECISE) pilot study. Br J Nutr 99:1190-1198
63. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014-10019
64. Rooseboom M, Vermeulen NPE, Durgut F, Commandeur JNM (2002) Comparative study on the bioactivation mechanisms and cytotox-icity of Te-phenyl-L- tellurocysteine, Se-phenyl-L-selenocysteine, and S-phenyl-L-cysteine. Chem Res Toxicol 15:1610-1618 (Pubitemid 36008209)
65. Rudolf E, Králová V, Cervinka M (2008) Selenium and colon cancer-from chemoprevention to new treatment modality. Anticancer Agents Med Chem 8:598-602
66. Sanmartín C, Plano D, Palop JA (2008) Selenium compounds and apoptotic modulation: a new perspective in cancer therapy. Mini Rev Med Chem 8:1020-1031
67. Scher HI, Mazumdar M, Kelly WK (1996) Clinical trials in relapsed prostate cancer: Defining the target. J Natl Canc Inst 88:1623-1634 (Pubitemid 26384808)
68. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64:9209-9216 (Pubitemid 39665537)
69. Shankar S, Srivastava RK (2008) Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 615:261-298
70. Singh U, Null K, Sinha R (2008) In vitro growth inhibition of mouse mammary epithelial tumor cells by methylseleninic acid: involvement of protein kinases. Mol Nutr Food Res 52:1281-1288
71. Sinha R, El-Bayoumy K (2004) Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 4:13-28 (Pubitemid 38332561)
72. Sinha R, Pinto JT, Facompre N, Kilheffer J, Baatz JE, El-Bayoumy K (2008) Effects of naturally occurring and synthetic organosele-nium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Nutr Cancer 60:267-275 (Pubitemid 351451281)
73. Sinha R, Sinha I, Null K, King T, Wolter W, Suckow M (2009) Methylseleninic acid inhibits HIF-1a in hormone refractory prostate cancer. [Abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 18-22 April 2009, Denver, CO. AACR, Philadelphia (Abstract # 5583)
74. Spallholz JE, Shriver BJ, Reid TW (2001) Dimethyldiselenide and methylseleninic acid generate superoxide in an in vitro chemi-luminescence assay in the presence of glutathione: implications for the anticarcinogenic activity of L-selenomethionine and L-Se-methylselenocysteine. Nutr Cancer 40:34-41 (Pubitemid 34037512)
75. Stevens JL, Robbins JD, Byrd RA (1986) A purified cysteine conjugate b-lyase from rat kidney cytosol Requirement for an a-keto acid or an amino acid oxidase for activity and identity with soluble glutamine transaminase K. J Biol Chem 261:15529-15537 (Pubitemid 17208779)
76. Sun Y, Nonobe E, Kobayashi Y, Kuraishi T, Aoki F, Yamamoto K, Sakai S (2002) Characterization and expression of L-amino acid oxidase of mouse milk. J Biol Chem 277:19080-19086 (Pubitemid 34952473)
77. Suzana S, Cham BG, Ahmad Rohi G, Mohd Rizal R, Fairulnizal MN, Normah H, Fatimah A (2009) Relationship between selenium and breast cancer: a case-control study in the Klang Valley. Singapore Med J 50:265-269
78. Suzuki KT, Tsuji Y, Ohta Y, Suzuki N (2008) Preferential organ distribution of methylselenol source Se-methylselenocysteine relative to methylseleninic acid. Toxicol Appl Pharmacol 227:76-83 (Pubitemid 351179845)
79. Tsuji Y, Suzuki N, T Suzuki K, Ogra Y (2009) Selenium metabolism in rats with long-term ingestion of Se-methylselenocysteine using enriched stable isotopes. J Toxicol Sci 34:191-200
80. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678 (Pubitemid 40282724)
81. Unni E, Koul D, Yung W-K, Sinha R (2005) Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro. Breast Cancer Res 7:R699-R707
82. Vanommeslaeghe K, Loverix S, Geerlings P, Tourwé D (2005) DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors. Bioorg Med Chem 13:6070-6082 (Pubitemid 41399918)
83. Venkateswaran V, Klotz LH, Fleshner NE (2002) Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 62:2540-2545 (Pubitemid 34462732)
84. Vigushin DM, Coombes RC (2004) Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets 4:205-218 (Pubitemid 38332557)
85. Wang Z, Jiang C, Lu J (2002) Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 34:113-120 (Pubitemid 34747321)
86. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D, Chiao JW (2008) De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33:375-380
87. Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P (2009) Increased expression of histone deacetylases (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1:62-71
88. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69:958-966
89. Wessjohann LA, Schneider A, Abbas M, Brandt W (2007) Selenium in chemistry and biochemistry in comparison to sulfur. Biol Chem 388:997-1006 (Pubitemid 47584312)
90. Whanger PD (2004) Selenium and its relationship to cancer: an update. Br J Nutr 91:11-28 (Pubitemid 38100556)
91. Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC (2009) Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 125:774-782
92. (Erratum in: Int J Cancer (2009) 125:1995)
93. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-5552 (Pubitemid 47255934)
94. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W (2005) Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacet-ylation. EMBO J 24:1021-1032 (Pubitemid 40470150)
95. Zeng H, Wu M, Botnen JH (2009) Methylselenol, a selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular- regulated kinase 1/2 pathway and other cancer signaling genes. J Nutr 139:1613-1618